Table 1 Clinical, epidemiological, and virological characteristics of HIV and HIV/HCV-coinfected patients
HIV | HIV/HCV | p-value | |
|---|---|---|---|
No | 27 | 28 | |
Age (years) | 51 (46; 53) | 48.5 (45.5; 53) | 0.272 |
Gender (male) | 16 (59.3%) | 19 (67.9%) | 0.508 |
BMI (kg/m2) | 25 (23.4; 26.7) | 24 (20.8; 26) | 0.125 |
BMI ≥ 25 (kg/m2) | 14 (51.9%) | 9 (32.1%) | 0.139 |
Diabetes | 4 (14.8%) | 2 (7.1%) | 0.362 |
High alcohol intake | 1 (3.7%) | 13 (46.4%) | < 0.001 |
HIV acquired by IVDU | 0 (0%) | 22 (78.6%) | < 0.001 |
Prior AIDS | 10 (37%) | 8 (28.6%) | 0.504 |
Years since HIV infection | 22.5 (17.5; 26.5) | – | |
Years since HCV diagnosis | 13 (12; 23) | – | |
Previous HCV therapy (IFNα + rib) | 13 (46.4%) | – | |
Antiretroviral therapy | 27 (100%) | 28 (100%) | 0.999 |
PI-based | 6 (22.2%) | 6(21.43%) | 0.019 |
2NRTI + II-based | 3 (11.1%) | 11 (39.3%) | |
2NRTI + PI-based | 0 (0%) | 3 (10.7%) | |
2NRTI + NNRTI-based | 16 (59.3%) | 7 (25%) | |
Others | 2 (7.4%) | 1 (3.6%) | |
HIV markers | |||
Nadir CD4 + T-cells | 261 (99; 402) | 185 (72; 269) | 0.155 |
Nadir CD4 + T-cells < 200 cells/mm3 | 11 (44%) | 15 (53.6%) | 0.487 |
CD4 + T-cells | 804 (685; 1036) | 678.5 (446.5; 906) | 0.026 |
CD4 + T-cells < 500 cells/mm3 | 0 (0%) | 8 (28.6%) | 0.003 |
HIV-RNA > 50 cp/mL | 0 (0%) | 0 (0%) | – |
HCV markers | |||
HCV genotype | |||
1 | 18 (64.3%) | – | |
2 | 1 (3.6%) | ||
3 | 8 (28.6%) | ||
4 | 1 (3.6%) | ||
Log10 HCV-RNA (IU/mL) | 6.3 (5.8; 6.6) | – | |
HCV-RNA > 850.000 IU/mL | 19 (67.9%) | – | |
Non-invasive fibrosis indexes | |||
FIB-4 | 1 (0.9; 1.2) | 2.6 (1.9; 3.2) | < 0.001 |
FIB-4 ≥ 3.25 | 0 (0%) | 7 (25%) | 0.006 |
LSM (Kpa) | 11.9 (9.7; 19.2) | – | |
F0–F1 (< 7.1 kPa) | 2 (7.1%) | – | |
F2 (7.1–9.4 kPa) | 5 (17.9%) | ||
F3 (9.5–12.4 kPa) | 8 (28.6%) | ||
F4 (≥ 12.5 kPa) | 13 (46.4%) | ||